Literature DB >> 11809259

Association between hepatitis C virus seropositivity, carotid-artery plaque, and intima-media thickening.

Nobukazu Ishizaka, Yuko Ishizaka, Eiko Takahashi, Ei ichi Tooda, Hideki Hashimoto, Ryozo Nagai, Minoru Yamakado.   

Abstract

We investigated the relation between positivity for hepatitis C virus (HCV) and carotid-artery plaque and carotid intima-media thickening by analysing cross-sectional data of individuals undergoing a general health screening test. Of 4784 individuals enrolled, 104 (2.2%) were seropositive for HCV. After adjustment for confounding risk factors, HCV seropositivity was found to be associated with an increased risk of carotid-artery plaque (odds ratio 1.92 [95% CI 1.56-2.38], p=0.002) and carotid intima-media thickening (2.85 [2.28-3.57], p<0.0001). These findings suggest a possible role for chronic hepatitis C in the pathogenesis of carotid arterial remodelling.

Entities:  

Mesh：

Year:  2002        PMID： 11809259     DOI： 10.1016/s0140-6736(02)07339-7

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


  75 in total

1.  Risk of myocardial infarction associated with chronic hepatitis C virus infection: a population-based cohort study.

Authors:  K A Forde; K Haynes; A B Troxel; S Trooskin; M T Osterman; S E Kimmel; J D Lewis; V Lo Re
Journal:  J Viral Hepat       Date:  2011-11-13       Impact factor: 3.728

2.  Evidence for association between hepatitis C virus seropositivity and coronary artery disease.

Authors:  C Vassalle; S Masini; F Bianchi; G C Zucchelli
Journal:  Heart       Date:  2004-05       Impact factor: 5.994

3.  Carotid intima-media thickness is increased in subjects with ischemic heart disease having a familial incidence.

Authors:  Chiharu Kishimoto; Miki Hirata; Kaori Hama; Masami Tanaka; Kazushi Nishimura; Shigeru Kubo; Kinzo Ueda; Tatsuo Fujioka; Shunichi Tamakil
Journal:  Exp Clin Cardiol       Date:  2006

Review 4.  Hepatitis C virus and metabolic disorder interactions towards liver damage and atherosclerosis.

Authors:  Umberto Vespasiani-Gentilucci; Paolo Gallo; Antonio De Vincentis; Giovanni Galati; Antonio Picardi
Journal:  World J Gastroenterol       Date:  2014-03-21       Impact factor: 5.742

Review 5.  Chronic HCV infection and inflammation: Clinical impact on hepatic and extra-hepatic manifestations.

Authors:  Rosa Zampino; Aldo Marrone; Luciano Restivo; Barbara Guerrera; Ausilia Sellitto; Luca Rinaldi; Ciro Romano; Luigi E Adinolfi
Journal:  World J Hepatol       Date:  2013-10-27

Review 6.  The procoagulant envelope virus surface: contribution to enhanced infection.

Authors:  Edward L G Pryzdial; Michael R Sutherland; Wolfram Ruf
Journal:  Thromb Res       Date:  2014-05       Impact factor: 3.944

Review 7.  Assessing cardiovascular risk in hepatitis C: An unmet need.

Authors:  Javier Ampuero; Manuel Romero-Gómez
Journal:  World J Hepatol       Date:  2015-09-08

8.  Association of hepatitis C with markers of hemostasis in HIV-infected and uninfected women in the women's interagency HIV study (WIHS).

Authors:  Elizabeth M Kiefer; Qiuhu Shi; Donald R Hoover; Robert Kaplan; Russell Tracy; Michael Augenbraun; Chenglong Liu; Marek Nowicki; Phyllis C Tien; Mardge Cohen; Elizabeth T Golub; Kathryn Anastos
Journal:  J Acquir Immune Defic Syndr       Date:  2013-03-01       Impact factor: 3.731

9.  Increased all-cause, liver, and cardiac mortality among hepatitis C virus-seropositive blood donors.

Authors:  Anne M Guiltinan; Zhanna Kaidarova; Brian Custer; Jennie Orland; Angela Strollo; Sherri Cyrus; Michael P Busch; Edward L Murphy
Journal:  Am J Epidemiol       Date:  2008-01-17       Impact factor: 4.897

10.  Association of HIV infection and HIV/HCV coinfection with C-reactive protein levels: the fat redistribution and metabolic change in HIV infection (FRAM) study.

Authors:  Jason Reingold; Christine Wanke; Donald Kotler; Cora Lewis; Russell Tracy; Steven Heymsfield; Phyllis Tien; Peter Bacchetti; Rebecca Scherzer; Carl Grunfeld; Michael Shlipak
Journal:  J Acquir Immune Defic Syndr       Date:  2008-06-01       Impact factor: 3.731
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.